Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny

Group 1 - Hims & Hers Health, Inc. (NYSE:HIMS) is currently one of the most shorted stocks recommended by analysts, with Canaccord Genuity lowering its price target from $68 to $30 while maintaining a Buy rating [1][2] - The lawsuit from Novo Nordisk alleges that Hims & Hers engaged in "unlawful mass marketing" of its semaglutide medications, claiming patent infringement [1][2] - The FDA has indicated plans to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded medications, which affects Hims & Hers [2] Group 2 - Hims & Hers Health, Inc. operates as a consumer-focused telehealth company, providing personalized healthcare and wellness services through a digital platform that connects patients with licensed medical professionals [3] - The company offers a range of treatments in categories such as sexual health, mental health, dermatology, and primary care [3]